- Industry shift to telemedicine has created sustaining change.
- Increasing public awareness and expectations.
- 75% of sponsors now incorporating virtual elements into studies.1
- 73% of sites commit to using telemedicine after pandemic.2
Global Regulatory Support
- Regulators around the world issued guidance supporting shift to DCT.
- FDA published commitment supporting decentralized approaches.3
Widespread Industry Support
- Over 100 pharma, CROs, site networks, advocacy groups, along with FDA have committed to DTC adoption through DTRA.
1. Survey Report: Virtual Trials and the COVID-19 Pandemic, June 2020
2. WCG CenterWatch